N/A
N=196
Discharge Opioid Education to Decrease Opioid Use After Cesarean
Opioid Use
Bottom Line
View on ClinicalTrials.gov: NCT03678870 ↗Enrolled (actual)
196
Serious AEs
0.0%
Results posted
Feb 2020
Primary outcome: Primary: Opioid Use — 7.5; 10 hydrocodone tablets
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Opioid Education Handout (Other)
- Age
- Adult · 18+ yrs
- Sex
- Female
- Sponsor
- Vanderbilt University Medical Center
- Primary completion
- Feb 2019
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Opioid Use |
7.5; 10 | — |
| SECONDARY Disposed of Opioids Correctly |
30; 14 | — |
| SECONDARY Analgesic Quiz Score |
10; 8 | — |
| SECONDARY Additional Prescriptions |
4; 1 | — |
Summary
Background: The number of opioid overdose deaths in the United States has quadrupled in 15 years, a dramatic manifestation of the current opioid abuse epidemic. This rise parallels a sharp increase in the amount of legal prescription opioids dispensed. The abundance of prescription opioids available is a primary pathway for opioid abuse and diversion and higher opioid use after surgery has been associated with an increased risk of chronic opioid use. Reducing the amount of opioid used after cesarean delivery may decrease the risk of chronic opioid use and will help towards better estimating and reducing the amount of opioids prescribed at discharge.
Objective: To to compare discharge opioid education to standard care to ascertain whether opioid education reduces opioid use after hospital discharge
Eligibility Criteria
Inclusion Criteria
- Women 18-45 years old
- Women undergoing cesarean delivery at VUMC
Exclusion Criteria
- Major post-surgical complications:
- cesarean hysterectomy, bowel or bladder injury, reoperation, ICU admission, wound infection or separation
- Chronic opioid use: Taking buprenorphine during pregnancy, taking an opioid for > 7 days during pregnancy.
- Women who do not speak English
Data sourced from ClinicalTrials.gov (NCT03678870). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.